Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

NCT00803244 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Disease

Interventions

DRUG: 300 IR
DRUG: Placebo

Sponsor

Stallergenes Greer